- Home
- RXT vs DMAC Comparison
RXT vs DMAC Comparison
Compare RXT & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXT
- DMAC
- Stock Information
- Founded
- RXT 1998
- DMAC 2000
- Country
- RXT United States
- DMAC United States
- Employees
- RXT N/A
- DMAC N/A
- Industry
- RXT EDP Services
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- RXT Technology
- DMAC Health Care
- Exchange
- RXT Nasdaq
- DMAC Nasdaq
- Market Cap
- RXT 280.1M
- DMAC 310.1M
- IPO Year
- RXT 2020
- DMAC N/A
- Fundamental
- Price
- RXT $1.44
- DMAC $6.87
- Analyst Decision
- RXT Hold
- DMAC Strong Buy
- Analyst Count
- RXT 5
- DMAC 3
- Target Price
- RXT $1.58
- DMAC $12.33
- AVG Volume (30 Days)
- RXT 1.1M
- DMAC 448.5K
- Earning Date
- RXT 11-11-2025
- DMAC 11-12-2025
- Dividend Yield
- RXT N/A
- DMAC N/A
- EPS Growth
- RXT N/A
- DMAC N/A
- EPS
- RXT N/A
- DMAC N/A
- Revenue
- RXT $2,693,100,000.00
- DMAC N/A
- Revenue This Year
- RXT N/A
- DMAC N/A
- Revenue Next Year
- RXT $1.59
- DMAC N/A
- P/E Ratio
- RXT N/A
- DMAC N/A
- Revenue Growth
- RXT N/A
- DMAC N/A
- 52 Week Low
- RXT $1.00
- DMAC $3.19
- 52 Week High
- RXT $3.41
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- RXT 56.67
- DMAC 63.84
- Support Level
- RXT $1.32
- DMAC $6.83
- Resistance Level
- RXT $1.52
- DMAC $7.41
- Average True Range (ATR)
- RXT 0.10
- DMAC 0.43
- MACD
- RXT 0.01
- DMAC 0.03
- Stochastic Oscillator
- RXT 73.33
- DMAC 73.62
About RXT Rackspace Technology Inc.
Rackspace Technology Inc is an end-to-end, hybrid, multi cloud technology services company. It designs, builds and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services; Data; Colocation; Cloud; Managed Hosting; Professional Services; and Security & Compliance. It operates in segments namely, Private Cloud, and Public Cloud. It generates revenue through the sale of consumption-based contracts for its service offerings and from the sale of professional services related to designing and building custom solutions.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.